Department of Biological Sciences, Clemson University, 190 Collings Street, Clemson, SC 29634, USA.
Int J Mol Sci. 2018 Jan 7;19(1):177. doi: 10.3390/ijms19010177.
NKG2D (natural killer group 2, member D) is an important activating receptor in natural killer (NK) cells and some T cells. NKG2D ligands (NKG2DLs) are specifically expressed on most tumor cells. The engagement of these ligands on tumor cells to NKG2D on NK cells will induce cell-mediated cytotoxicity and have target cells destroyed. This gives NKG2D/NKG2DLs great potential in cancer therapeutic application. The creation of NKG2D/NKG2DL-based multi-functional fusion proteins is becoming one of the most promising strategies in immunotherapy for cancer. Antibodies, cytokines, and death receptors have been fused with NKG2D or its ligands to produce many powerful fusion proteins, including NKG2D-based chimeric antigen receptors (CARs). In this article, we review the recent developments of the fusion proteins with NKG2D/NKG2DL ligands in cancer immunotherapy.
NKG2D（自然杀伤细胞组 2，成员 D）是自然杀伤（NK）细胞和一些 T 细胞中的一种重要激活受体。NKG2D 配体（NKG2DLs）特异性表达于大多数肿瘤细胞上。这些配体与 NK 细胞上的 NKG2D 结合，将诱导细胞介导的细胞毒性，并使靶细胞被破坏。这使得 NKG2D/NKG2DL 在癌症治疗应用中有很大的潜力。基于 NKG2D/NKG2DL 的多功能融合蛋白的构建正在成为癌症免疫治疗中最有前途的策略之一。抗体、细胞因子和死亡受体已与 NKG2D 或其配体融合，产生了许多强大的融合蛋白，包括基于 NKG2D 的嵌合抗原受体（CAR）。本文综述了 NKG2D/NKG2DL 配体在癌症免疫治疗中的融合蛋白的最新研究进展。
